TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12890273
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy treatment for 12 weeks
Study: 8550780
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg esterified estrogen and 2.5 mg methyltestosterone (E+A)
Study: 8550780
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg conjugated equine estrogen (CEE)
Study: 6619040
Drug: ticarcillin (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin (4.0 g every 6 h for 7 days)
Study: 6619040
Drug: mezlocillin (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (4.0 g every 6 h for 7 days)
Study: 6619040
Drug: placebo (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (4.0 g every 6 h for 7 days)
Study: 27262871
Drug: Progesterone with
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone with or without hypothermia (exact dosage and duration not specified)
Study: 20708421
Drug: 5 mg/mL
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/mL formulation of rhGH Nutropin AQ
Study: 20708421
Drug: 2.5 mg/mL
Normalized name: iodine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/mL formulation of rhGH Nutropin AQ
Study: 20708421
Drug: 10 mg/mL
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL formulation of rhGH Nutropin AQ
Study: 17032732
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist Cetrorelix with recombinant FSH (rFSH) in group A (n = 52)
Study: 17032732
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist Cetrorelix with rFSH in group A
Study: 12030546
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17beta-estradiol (E2)
Study: 12030546
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-estradiol (E2)
Study: 12030546
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17beta-estradiol (E2)
Study: 1847582
Drug: Provera 20
Normalized name: Provera 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provera 20 mg
Study: 1847582
Drug: Premarin 0.6
Normalized name: Premarin 0.625mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 0.6 mg
Study: 1847582
Drug: Premarin 0.3
Normalized name: Premarin 0.3mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 0.3 mg plus Provera 10 mg
Study: 25870994
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg once daily)
Study: 16952918
Drug: TEA (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA (lidocaine 2 mg kg(‐1) followed by 3 mg kg(‐1) h(‐1) epidurally)
Study: 6731693
Drug: Sequential pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pneumatic leg compression at pressures of 90 to 100 mm Hg
Study: 6731693
Drug: Sequential pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pneumatic leg compression at pressures of 35 mm Hg
Study: 6731693
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 units three times per day
Study: 6731693
Drug: Sequential pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pneumatic leg compression at pressures of 35 to 55 mm Hg
Study: 26660709
Drug: Medication (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (not specified if it was part of the intervention)
Study: 10445378
Drug: Ipsapirone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone (0.3 mg/kg body weight)
Study: 341905
Drug: Halopredone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halopredone acetate cream (0.01%)
Study: 30953556
Drug: iBobbly app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: iBobbly app (self-help app based on acceptance and commitment therapy)
Study: 23630367
Drug: Injection plus
Normalized name: Bimectin Plus Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection plus exercise (n = 115)
Study: 16479024
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (0.25 mg/day)
Study: 14757613
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin use (> or =2 standard aspirin tablets/wk)
Study: 14757613
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use of 0.5 to 1.5 standard tablets per week
Study: 14757613
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use of 2 to 5 tablets per week
Study: 14757613
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use of 6 to 14 tablets per week
Study: 14757613
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use of more than 14 tablets per week
Study: 14757613
Drug: Regular short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular short-term aspirin use (< or =5 years)
Study: 14757613
Drug: Regular long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular long-term aspirin use (>5 years)
Study: 14757613
Drug: Increasing duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing duration of aspirin use
Study: 11511404
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg
Study: 21355143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Fluoxetine)
Study: 3074627
Drug: Thymic hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thymic hormone
Study: 3074627
Drug: Pentapeptide treatment
Normalized name: pentapeptide-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentapeptide treatment
Study: 3074627
Drug: Thymic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymic therapy
Study: 20349684
Drug: adapalene 0.1%-benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: adapalene 0.1%-benzoyl peroxide 2.5% (A/BPO) fixed-dose combination gel with doxycycline hyclate 100 mg
Study: 18490245
Drug: 8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Gy + zoledronic acid (4 mg iv, in 15‐min infusions)
Study: 18490245
Drug: 6 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Gy + zoledronic acid (4 mg iv, in 15‐min infusions)
Study: 8604620
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin titrated to an activated partial thromboplastin time (aPTT) of 1.5 to 2.0 times control for 72 to 96 hours
Study: 8604620
Drug: Optimal anticoagulation
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal anticoagulation (all aPTTs >60 seconds, all heparin levels>0.2 U/ml)
Study: 8604620
Drug: Aggressive (high-intensity)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive (high-intensity) anticoagulation with heparin to achieve aPTTs >2.0 times control
Study: 8604620
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy with heparin and aspirin
Study: 1940267
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg intravenous)
Study: 25817849
Drug: Dexamethasone, 1
Normalized name: Dexamethasone, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 1 mg/kg, intravenous at induction of anesthesia
Study: 16709935
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain of 5% or less during the first 2 months of intensive phase therapy among underweight patients
Study: 15250174
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Durodont Zahnweiss intensiv (RDA 166) and Durodont medical fresh and white
Study: 26874390
Drug: Beetroot Juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot Juice (BRJ) - 6.1 mmol nitrate, daily for 1 week
Study: 26874390
Drug: Beetroot Juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot Juice (BRJ) - 6.1 mmol nitrate, single acute dose
Study: 14730655
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 50 mcg twice daily (FP 100)
Study: 14730655
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 125 mcg twice daily (FP 250)
Study: 11344825
Drug: HRT (cyclical
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (cyclical conjugated estrogens 0.625 mg/day plus medrogestone 5 mg/day)
Study: 31834156
Drug: Intravaginal ovule
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ovule containing 0.03mg estriol, treated daily for 16 weeks (Group A)
Study: 28030601
Drug: Normal ionized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal ionized calcium target range (1.1‐1.2 mmol/l)
Study: 28030601
Drug: Low ionized
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ionized calcium target range (0.95‐1.05 mmol/l)
Study: 24411798
Drug: Perceived student
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived student drug testing
Study: 22446569
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone based monitoring (twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback)
Study: 15226691
Drug: Cotrimoxazole prophylaxis
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole prophylaxis (one tablet per day)
Study: 9431728
Drug: 5-sessions exposure
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-sessions exposure and cognitive restructuring (6 hr gradual treatment)
Study: 3306379
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine administered at 3, 4, 6, and 14 months.
Study: 28463161
Drug: PRO-CTCAE self-reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-CTCAE self-reporting during treatment
Study: 28463161
Drug: PRO-CTCAE self-reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-CTCAE self-reporting after treatment
Study: 24035250
Drug: Intravenous secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous secukinumab (2×10 mg/kg)
Study: 16565959
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg dose of alcohol
Study: 14571231
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (0.20 to 0.33 mg/kg body weight per week for 4 years)
Study: 10910439
Drug: Essential hypertension
Normalized name: OILS,ESSENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential hypertension (no treatment)
Study: 9010707
Drug: Matrix-type transdermal
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-type transdermal therapeutic system (MTTS)
Study: 9010707
Drug: Reservoir-type transdermal
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reservoir-type transdermal therapeutic system (RTTS)
Study: 1558156
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg/100 ml in 5 min)
Study: 1558156
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 micrograms/100 ml)
Study: 23864249
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg over a 30 min infusion) every 1 month
Study: 23864249
Drug: Clodronate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (4 tablets per day of 1,600 mg)
Study: 21081641
Drug: Enhanced Green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Green Prescription intervention (written exercise prescription, brief advice from a primary care nurse, face-to-face follow-up at 6 months, and 9 months of telephone support)
Study: 21081641
Drug: Enhanced Green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Green Prescription intervention
Study: 15503310
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan treatment
Study: 11317685
Drug: Stainless steel
Normalized name: stainless steel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stainless steel implants
Study: 9446435
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg on the day of operation and 3 x 25 mg orally from postoperative day 1 to 10)
Study: 9446435
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 6 Gy radiation (administered within postoperative days 1 to 4)
Study: 7957539
Drug: Glycopyrrolate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (1 mg i.v.)
Study: 7957539
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg orally)
Study: 3311818
Drug: QU.A.RT. group
Approvals — FDA: no, EMA: no, PMDA: no
Description: QU.A.RT. group (irradiated on the operated breast with a total dose of 50 Gy plus a limited boost of 10 Gy)
Study: 15589635
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n=103)
Study: 9707354
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg manidipine dihydrochloride
Study: 7880702
Drug: suxamethonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.25 mg kg‐1
Study: 2099158
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin (2 gm) and sulbactam (1 gm)
Study: 12154207
Drug: Sulphasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (2 g/day)
Study: 33875
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose sodium cromoglycate (2 g/day)
Study: 33875
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sodium cromoglycate (160 mg/day)
Study: 29039261
Drug: High-intensity exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity exercise program (9-month, thrice-weekly, 10-minute sessions)
Study: 19047322
Drug: Fluoxetine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (after excluding one large trial)
Study: 17612822
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg/day) plus placebo
Study: 17612822
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg/day) plus bupropion (50 mg/day)
Study: 12202072
Drug: Wheeling Walks
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wheeling Walks campaign promoting 30 min of daily walking through paid media, public relations, and public health activities
Study: 12202072
Drug: Wheeling Walks
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wheeling Walks campaign promoting 30 min of daily walking
Study: 29036330
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments in multi-arm trials
Study: 18361007
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% plus ketamine 0.5 mg/kg (group BK)
Study: 18361007
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% plus tramadol 1 mg/kg (group BT)
Study: 16818127
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (8 g)
Study: 10758457
Drug: Ketamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.1 mg kg‐1)
Study: 10758457
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg kg‐1)
Study: 8951191
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (5 mg kg‐1)
Study: 8951191
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (5 mg kg‐1)
Study: 8951191
Drug: Intrarectal artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal artemether (5 mg kg‐1)
Study: 25788509
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment in PAC
Study: 20060783
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole (25 mg aspirin plus 200 mg dipyridamole) twice daily within 24 hours of stroke or TIA onset.
Study: 20060783
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole (100 mg aspirin) once daily after 7 days of aspirin monotherapy.
Study: 17587504
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg/day) + Bupropion SR (300 mg/day)
Study: 12079730
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg/day)
Study: 16150793
Drug: Caffeine capsules
Normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsules (5 mg kg(‐1))
Study: 16150793
Drug: High-dose adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenaline infusion (HAdr; adrenaline concentration, 1.2 nM)
Study: 16150793
Drug: Low-dose adrenaline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adrenaline infusion (LAdr; adrenaline concentration, 0.75 nM)
Study: 8889901
Drug: Tirilazad (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad (2.5 mg/kg every 3 hours for the first 12 hours, then 2.5 mg/kg every 6 hours for a total of 22 doses over 5 days)
Study: 27609859
Drug: Allopurinol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (up to 600 mg daily)
Study: 16630986
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin (6 mg loading dose followed by 3 mg/day for 14 days)
Study: 15197517
Drug: Nateglinide alone
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide alone (120 mg)
Study: 15197517
Drug: Nateglinide with
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide with sulfinpyrazone (400 mg/day for 7 days)
Study: 11074103
Drug: Lithium (N=15),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (N=15), administered twice daily in doses varying from 1050 to 1950 mg (mean=1569 mg) for 3 weeks.
Study: 11074103
Drug: Placebo (N=15),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (N=15), administered for 3 weeks.
Study: 9091474
Drug: Cyclosporine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 3.0 mg/kg per day
Study: 9091474
Drug: Cyclosporine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 1.5 mg/kg per day
Study: 9091474
Drug: Cyclosporine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 5.0 mg/kg per day (induction phase)
Study: 22852580
Drug: BRN-01 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRN-01 tablets (homeopathic medicine containing Actaea racemosa, Arnica montana, Glonoinum, Lachesis mutus, Sanguinaria canadensis)
Study: 22852580
Drug: BRN-01 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRN-01 tablets
Study: 20598970
Drug: Implantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN)
Study: 18606966
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (Dysport) treatment
Study: 8877019
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nalmefene in young subjects (n=18)
Study: 8877019
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nalmefene in elderly subjects (n=11)
Study: 8877019
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nalmefene in young subjects (n=8)
Study: 8877019
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nalmefene in elderly subjects (n=15)
Study: 6348635
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin E
Study: 27652041
Drug: PBC &
Normalized name: Phenobarbital, Belladonna, and Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBC & RBS herbal medicine
Study: 25191937
Drug: ICSI/PGS treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICSI/PGS treatment
Study: 25191937
Drug: Standard ICSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ICSI treatment